BioSpace News Archive

Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2019 third quarter ended March 31, 2019 on Tuesday, May 7, 2019 after the close of the stock market.

Canopy Health’s new service area to include top-rated medical group and hospital

Medicure Inc., a pharmaceutical company, will release financial results for the year ended December 31, 2018 after markets close on Monday, April 29, 2019.

New project will improve access to vaccination and increase vaccine coverage

he SanBio Group announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted for SB623 for the treatment of patients with motor deficits arising from Acquired Brain Injury, including traumatic brain injury, ischemic stroke and haemorrhagic stroke.

Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant to a research team at University of California, Los Angeles to perform a natural disease history study of adult midline gliomas, a certain type of aggressive brain tumors.

Agendia, Inc., a world leader in precision oncology, today announced the publication of study results for BluePrint®, its 80-gene proprietary molecular subtyping test, in Nature Breast Cancer

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington’s Disease (HD) and a phase 3 study in another rare neurological disease.

SEngine Precision Medicine, an oncology startup accelerating cancer drug discovery through its proprietary diagnostic tool known as the PARIS Test®, today welcomed Dr. Jonathan Baell to the SEngine Precision Medicine Scientific Advisory Board.

Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced results from the interim safety review conducted by the Independent Data Monitoring Committee (“IDMC”) on 21 March 2019.